In recent years regenerative cell therapies utilizing the pluripotency of hESCs or iPSCs are gaining ground and hold promise to outpace conventional treatment options for cardiac, kidney, liver, neuronal and other diseases in years to come. However, engineering and maneuvering these very unique cell types remains challenging.
While the regulatory guidelines for this novel therapeutic modality are still being worked out, Molecular Devices introduced a hSC engineering workflow with the CloneSelect® Single-Cell Printer™ and CloneSelect® Imager. This enables high throughput screening of engineered iPS and ES clones by preserving traceability with assurance of monoclonality while maintaining their normal genetic integrity, pluripotency and cellular functionality. The implementation of these technologies enabled the AstraZeneca team to build a unique collection of hundreds of clonal iPSC and ESC lines to develop a deeper understanding regenerative therapies to come.